Volvo Sold 11,742 Passenger Vehicles In Mainland China In Jan

Feb 3 (Reuters) - Biogaia AB: * BOARD PROPOSES THAT UPCOMING ANNUAL GENERAL MEETING ON 5 MAY 2023 APPROVES AN ORDINARY DIVIDEND ACCORDING TO POLICY OF SEK 1.45 (0.73) PER SHARE * BOARD PROPOSES AN

Feb 3 (Reuters) - Orexo AB: * OREXO SUBMITS NEW DRUG APPLICATION TO FDA FOR OX124, A HIGH-DOSE RESCUE MEDICATION FOR OPIOID OVERDOSE * OX124 IS DESIGNED TO REVERSE EFFECTS OF MOST POWERFUL SYNTHETIC

Feb 2 (Reuters) - Amgen Inc: * AMGEN - ANNOUNCED FDA APPROVED TEZSPIRE FOR SELF-ADMINISTRATION IN PRE-FILLED, SINGLE-USE PEN FOR PATIENTS AGED 12 YEARS & OLDER WITH SEVERE ASTHMA * AMGEN INC - FDA HAS

Feb 2 (Reuters) - AstraZeneca PLC: * ASTRAZENECA - TEZSPIRE APPROVED FOR SELF-ADMINISTRATION IN US WITH A NEW PRE-FILLED PEN Source text for Eikon: Further company coverage:

Feb 1 (Reuters) - Cantargia AB: * CANTARGIA ANNOUNCES APPOINTMENT OF PATRIK RENBLAD AS CHIEF FINANCIAL OFFICER * MR RENBLAD WILL ASSUME THIS ROLE BY AUGUST 2023, AT LATEST. Source text for Eikon:

Jan 30 (Reuters) - Isofol Medical AB (publ): * ISOFOL HAS OBTAINED A REQUEST TO CALL FOR AN EXTRAORDINARY GENERAL MEETING * OBTAINED A REQUEST TO CALL AN EXTRAORDINARY GENERAL MEETING TO ELECT A NEW

Jan 30 (Reuters) - Active Biotech AB publ: * ACTIVE BIOTECH CONFIRMS POSITIVE CLINICAL SAFETY PROFILE OF LAQUINIMOD EYE DROPS * NO SERIOUS ADVERSE EVENTS WERE REPORTED. * EYE DROP WAS SAFE AND WELL

Jan 27 (Reuters) - InDex Pharmaceuticals Holding AB : * INDEX PHARMACEUTICALS UPDATES THE TIMELINE OF THE PHASE III STUDY CONCLUDE WITH COBITOLIMOD * OUTCOME OF DOSE SELECTION EXPECTED TO BE AVAILABLE

Jan 27 (Reuters) - Devyser Diagnostics AB: * DEVYSER MAKES PROVISIONS DUE TO RETROACTIVE "PAYBACK" LEVY * DUE TO NEWLY-INTRODUCED "PAYBACK" LEVY IN ITALY, COMPANY WILL MAKE PROVISIONS FOR ITS COSTS IN

Jan 27 (Reuters) - Intellego Technologies AB: * CO'S DOSIMETER TESTED BY DRUG MANUFACTURER WITH POSITIVE RESULTS Source text for Eikon: Further company coverage: (Gdansk Newsroom)